SILVER SPRING, MD  -  NOVEMBER 5, 2019 -  Amicrobe held a pre-IND face-to-face meeting with the Office of Antimicrobial Products, Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA) at its White Oak Campus in Silver Spring, MD. The meeting was on Amicidin-β Solution and provided valuable feedback for the  development program, from manufacturing to nonclinical GLP toxicology studies to clinical development strategy, including guidance on the remaining non-clinical studies to file a successful IND.

​

​

​